[go: up one dir, main page]

AR023645A1 - Metodo para tratar una infeccion por estafilococos - Google Patents

Metodo para tratar una infeccion por estafilococos

Info

Publication number
AR023645A1
AR023645A1 ARP990104279A ARP990104279A AR023645A1 AR 023645 A1 AR023645 A1 AR 023645A1 AR P990104279 A ARP990104279 A AR P990104279A AR P990104279 A ARP990104279 A AR P990104279A AR 023645 A1 AR023645 A1 AR 023645A1
Authority
AR
Argentina
Prior art keywords
treat
staphilocos
infection
staphylococcal infections
lisostafine
Prior art date
Application number
ARP990104279A
Other languages
English (en)
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Publication of AR023645A1 publication Critical patent/AR023645A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La lisostafina es un antibiotico eficaz para el tratamiento de infecciones estafilococicas. Grandes dosis de lisostafina o de análogos de lisostafina soneficaces a corto plazo, o incluso en administraciones de una sola dosis, para tratar y erradicarinfecciones estafilococicas, incluyendo las que sonresistentes a los antibioticos convencionales.
ARP990104279A 1998-08-27 1999-08-26 Metodo para tratar una infeccion por estafilococos AR023645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/140,732 US6028051A (en) 1997-07-23 1998-08-27 Method for the treatment of staphylococcal disease

Publications (1)

Publication Number Publication Date
AR023645A1 true AR023645A1 (es) 2002-09-04

Family

ID=22492556

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104279A AR023645A1 (es) 1998-08-27 1999-08-26 Metodo para tratar una infeccion por estafilococos

Country Status (12)

Country Link
US (1) US6028051A (es)
EP (1) EP1107722B1 (es)
JP (1) JP2002523437A (es)
AR (1) AR023645A1 (es)
AT (1) ATE493145T1 (es)
AU (1) AU5811199A (es)
CA (1) CA2341699A1 (es)
DE (1) DE69943089D1 (es)
IL (1) IL141648A0 (es)
NO (1) NO20010953L (es)
WO (1) WO2000012049A2 (es)
ZA (1) ZA995444B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875903B2 (en) * 1998-06-22 2005-04-05 University Of Vermont Treatment of Staphylococcus infections
US7091332B1 (en) 1998-06-22 2006-08-15 University Of Vermont Treatment of staphylococcus infections
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20030211995A1 (en) * 2001-12-21 2003-11-13 Kokai-Kun John Fitzgerald Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
EP1465990B1 (en) * 2001-12-21 2011-07-13 Biosynexus Incorporated Truncated lysostaphin molecule with enhanced staphylolytic activity
US6759881B2 (en) * 2002-03-22 2004-07-06 Rambus Inc. System with phase jumping locked loop circuit
US7452533B2 (en) * 2002-03-26 2008-11-18 Biosynexus Incorporated Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol
WO2003082148A1 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
WO2004052308A2 (en) * 2002-12-10 2004-06-24 Biosynexus Incorporated Topical anti-infective formulations
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
WO2007041621A2 (en) * 2005-10-03 2007-04-12 Xingsheng Sean Ling Hybridization assisted nanopore sequencing
US20080095756A1 (en) * 2006-09-05 2008-04-24 Biosynexus Incorporated Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009150171A1 (en) * 2008-06-10 2009-12-17 Profos Ag Method of treatment of inflammatory diseases
CN112626055A (zh) 2014-05-14 2021-04-09 达特茅斯学院理事会 去免疫化溶葡萄球菌酶和使用方法
EP3485899A4 (en) 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze THERMOSTABLE COMPOSITION HAVING ANTIVIRAL AND ANTIBACTERIAL ACTION, AND USE THEREOF
CN113164564A (zh) * 2018-11-19 2021-07-23 诺尔玛克Ip股份有限公司 用于治疗或预防心内膜炎的安克洛酶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) * 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases

Also Published As

Publication number Publication date
CA2341699A1 (en) 2000-03-09
EP1107722B1 (en) 2010-12-29
NO20010953D0 (no) 2001-02-26
NO20010953L (no) 2001-03-21
EP1107722A2 (en) 2001-06-20
US6028051A (en) 2000-02-22
ZA995444B (en) 2000-07-10
EP1107722A4 (en) 2006-05-17
JP2002523437A (ja) 2002-07-30
DE69943089D1 (de) 2011-02-10
WO2000012049A2 (en) 2000-03-09
IL141648A0 (en) 2002-03-10
AU5811199A (en) 2000-03-21
ATE493145T1 (de) 2011-01-15
WO2000012049A3 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
AR023645A1 (es) Metodo para tratar una infeccion por estafilococos
ES2192201T3 (es) Compuestos de piranona utiles para el tratamiento de infecciones retrovirales.
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
ES2074563T3 (es) Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
EA200000594A1 (ru) Новые макролиды
CO4560547A1 (es) Una forma de dosis de azitromicina y un metodo de trata- miento de una infeccion microbiana que involucra la adminis- tracion de azitromicina
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
ES2186787T3 (es) Utilizacion de ritonavir (abt-538) para mejorar la farmacocinetica de medicamentos metabolizados por el citocromo p450 en un metodo de tratamiento del sida.
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
BR0112750A (pt) Aminopiperidina quinolinas e seus análogos azaisostéricos com atividade antibacteriana
ES2192101T3 (es) Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh.
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
UY26678A1 (es) El uso de composiciones a base de antibióticos de azalidos para tratar o prevenir una infección bacteriana o protozoaria en mamíferos
ES2042868T3 (es) Un metodo de producir galidermina.
AR029544A1 (es) Composiciones y metodos para tratar infecciones bacterianas
NO953995D0 (no) Ionenolymere som anthelmintica i dyr
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
ATE258375T1 (de) Behandlungen von der foulbroodbienenkrankheit
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
ES2075881T3 (es) Un microorganismo para la produccion selectiva de un componente especifico de avermectina y metodo para esta produccion selectiva.
ES2138976T3 (es) Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
ES2126795T3 (es) Formulacion y procedimiento de control de los nematodos parasitos de las plantas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure